nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—Pain—Carboplatin—bone cancer	0.0165	0.0243	CcSEcCtD
Scopolamine—Body temperature increased—Carboplatin—bone cancer	0.0152	0.0225	CcSEcCtD
Scopolamine—Amnesia—Cisplatin—bone cancer	0.0122	0.0181	CcSEcCtD
Scopolamine—Redness—Epirubicin—bone cancer	0.0121	0.0178	CcSEcCtD
Scopolamine—Redness—Doxorubicin—bone cancer	0.0112	0.0164	CcSEcCtD
Scopolamine—Irritability—Cisplatin—bone cancer	0.011	0.0162	CcSEcCtD
Scopolamine—Amblyopia—Epirubicin—bone cancer	0.0105	0.0155	CcSEcCtD
Scopolamine—Speech disorder—Methotrexate—bone cancer	0.0101	0.0149	CcSEcCtD
Scopolamine—Amblyopia—Doxorubicin—bone cancer	0.00976	0.0144	CcSEcCtD
Scopolamine—Conjunctivitis—Cisplatin—bone cancer	0.00862	0.0127	CcSEcCtD
Scopolamine—Depressed level of consciousness—Methotrexate—bone cancer	0.0084	0.0124	CcSEcCtD
Scopolamine—Bradycardia—Cisplatin—bone cancer	0.0081	0.0119	CcSEcCtD
Scopolamine—Urinary tract disorder—Cisplatin—bone cancer	0.00786	0.0116	CcSEcCtD
Scopolamine—Urethral disorder—Cisplatin—bone cancer	0.0078	0.0115	CcSEcCtD
Scopolamine—Visual impairment—Cisplatin—bone cancer	0.00767	0.0113	CcSEcCtD
Scopolamine—Dry eye—Epirubicin—bone cancer	0.00752	0.0111	CcSEcCtD
Scopolamine—Eye disorder—Cisplatin—bone cancer	0.00744	0.011	CcSEcCtD
Scopolamine—Flushing—Cisplatin—bone cancer	0.00739	0.0109	CcSEcCtD
Scopolamine—Arrhythmia—Cisplatin—bone cancer	0.00711	0.0105	CcSEcCtD
Scopolamine—Dry eye—Doxorubicin—bone cancer	0.00696	0.0103	CcSEcCtD
Scopolamine—Erythema—Cisplatin—bone cancer	0.00693	0.0102	CcSEcCtD
Scopolamine—Eczema—Epirubicin—bone cancer	0.00658	0.00969	CcSEcCtD
Scopolamine—Vision blurred—Cisplatin—bone cancer	0.00653	0.00963	CcSEcCtD
Scopolamine—Tremor—Cisplatin—bone cancer	0.00649	0.00957	CcSEcCtD
Scopolamine—Eczema—Doxorubicin—bone cancer	0.00608	0.00897	CcSEcCtD
Scopolamine—Irritability—Methotrexate—bone cancer	0.00603	0.00888	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.00586	0.00864	CcSEcCtD
Scopolamine—Oedema—Cisplatin—bone cancer	0.00566	0.00834	CcSEcCtD
Scopolamine—Nervous system disorder—Cisplatin—bone cancer	0.00555	0.00818	CcSEcCtD
Scopolamine—Tachycardia—Cisplatin—bone cancer	0.00552	0.00814	CcSEcCtD
Scopolamine—Skin disorder—Cisplatin—bone cancer	0.00549	0.0081	CcSEcCtD
Scopolamine—Hyperhidrosis—Cisplatin—bone cancer	0.00547	0.00806	CcSEcCtD
Scopolamine—Dry skin—Epirubicin—bone cancer	0.00542	0.00798	CcSEcCtD
Scopolamine—Hypotension—Cisplatin—bone cancer	0.00529	0.00779	CcSEcCtD
Scopolamine—Muscular weakness—Epirubicin—bone cancer	0.00521	0.00768	CcSEcCtD
Scopolamine—Dysphagia—Epirubicin—bone cancer	0.00511	0.00753	CcSEcCtD
Scopolamine—Dysuria—Methotrexate—bone cancer	0.0051	0.00752	CcSEcCtD
Scopolamine—Dry skin—Doxorubicin—bone cancer	0.00501	0.00739	CcSEcCtD
Scopolamine—Drowsiness—Methotrexate—bone cancer	0.00487	0.00717	CcSEcCtD
Scopolamine—Pain—Cisplatin—bone cancer	0.00484	0.00713	CcSEcCtD
Scopolamine—Muscular weakness—Doxorubicin—bone cancer	0.00482	0.00711	CcSEcCtD
Scopolamine—Dysuria—Epirubicin—bone cancer	0.00478	0.00704	CcSEcCtD
Scopolamine—Conjunctivitis—Methotrexate—bone cancer	0.00473	0.00697	CcSEcCtD
Scopolamine—Dysphagia—Doxorubicin—bone cancer	0.00473	0.00697	CcSEcCtD
Scopolamine—Sweating—Methotrexate—bone cancer	0.00467	0.00688	CcSEcCtD
Scopolamine—Feeling abnormal—Cisplatin—bone cancer	0.00466	0.00687	CcSEcCtD
Scopolamine—Drowsiness—Epirubicin—bone cancer	0.00455	0.00671	CcSEcCtD
Scopolamine—Body temperature increased—Cisplatin—bone cancer	0.00447	0.00659	CcSEcCtD
Scopolamine—Conjunctivitis—Epirubicin—bone cancer	0.00443	0.00652	CcSEcCtD
Scopolamine—Dysuria—Doxorubicin—bone cancer	0.00442	0.00651	CcSEcCtD
Scopolamine—Sweating—Epirubicin—bone cancer	0.00437	0.00644	CcSEcCtD
Scopolamine—Pharyngitis—Methotrexate—bone cancer	0.00434	0.00639	CcSEcCtD
Scopolamine—Urinary tract disorder—Methotrexate—bone cancer	0.00431	0.00636	CcSEcCtD
Scopolamine—Urethral disorder—Methotrexate—bone cancer	0.00428	0.00631	CcSEcCtD
Scopolamine—Drowsiness—Doxorubicin—bone cancer	0.00421	0.00621	CcSEcCtD
Scopolamine—Visual impairment—Methotrexate—bone cancer	0.00421	0.00621	CcSEcCtD
Scopolamine—Bradycardia—Epirubicin—bone cancer	0.00416	0.00613	CcSEcCtD
Scopolamine—Conjunctivitis—Doxorubicin—bone cancer	0.0041	0.00604	CcSEcCtD
Scopolamine—Eye disorder—Methotrexate—bone cancer	0.00408	0.00602	CcSEcCtD
Scopolamine—Asthenia—Cisplatin—bone cancer	0.00406	0.00598	CcSEcCtD
Scopolamine—Pharyngitis—Epirubicin—bone cancer	0.00406	0.00598	CcSEcCtD
Scopolamine—Sweating—Doxorubicin—bone cancer	0.00404	0.00595	CcSEcCtD
Scopolamine—Urinary tract disorder—Epirubicin—bone cancer	0.00404	0.00595	CcSEcCtD
Scopolamine—Urethral disorder—Epirubicin—bone cancer	0.00401	0.00591	CcSEcCtD
Scopolamine—Visual impairment—Epirubicin—bone cancer	0.00394	0.00581	CcSEcCtD
Scopolamine—Bradycardia—Doxorubicin—bone cancer	0.00385	0.00568	CcSEcCtD
Scopolamine—Mental disorder—Methotrexate—bone cancer	0.00383	0.00564	CcSEcCtD
Scopolamine—Eye disorder—Epirubicin—bone cancer	0.00382	0.00563	CcSEcCtD
Scopolamine—Erythema—Methotrexate—bone cancer	0.0038	0.00561	CcSEcCtD
Scopolamine—Flushing—Epirubicin—bone cancer	0.00379	0.00559	CcSEcCtD
Scopolamine—Pharyngitis—Doxorubicin—bone cancer	0.00375	0.00553	CcSEcCtD
Scopolamine—Urinary tract disorder—Doxorubicin—bone cancer	0.00374	0.00551	CcSEcCtD
Scopolamine—ABCB1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.00373	0.0116	CbGpPWpGaD
Scopolamine—Urethral disorder—Doxorubicin—bone cancer	0.00371	0.00547	CcSEcCtD
Scopolamine—Arrhythmia—Epirubicin—bone cancer	0.00365	0.00538	CcSEcCtD
Scopolamine—Visual impairment—Doxorubicin—bone cancer	0.00365	0.00537	CcSEcCtD
Scopolamine—Vomiting—Cisplatin—bone cancer	0.0036	0.0053	CcSEcCtD
Scopolamine—Vision blurred—Methotrexate—bone cancer	0.00358	0.00528	CcSEcCtD
Scopolamine—Mental disorder—Epirubicin—bone cancer	0.00358	0.00528	CcSEcCtD
Scopolamine—Rash—Cisplatin—bone cancer	0.00357	0.00526	CcSEcCtD
Scopolamine—Dermatitis—Cisplatin—bone cancer	0.00356	0.00525	CcSEcCtD
Scopolamine—Erythema—Epirubicin—bone cancer	0.00356	0.00525	CcSEcCtD
Scopolamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00355	0.0111	CbGpPWpGaD
Scopolamine—Eye disorder—Doxorubicin—bone cancer	0.00354	0.00521	CcSEcCtD
Scopolamine—Flushing—Doxorubicin—bone cancer	0.00351	0.00517	CcSEcCtD
Scopolamine—CHRM4—G alpha (i) signalling events—GRM4—bone cancer	0.0035	0.0109	CbGpPWpGaD
Scopolamine—CHRM4—G alpha (i) signalling events—RGS1—bone cancer	0.0035	0.0109	CbGpPWpGaD
Scopolamine—CHRM5—G alpha (q) signalling events—GRM1—bone cancer	0.00349	0.0109	CbGpPWpGaD
Scopolamine—Vertigo—Methotrexate—bone cancer	0.00342	0.00504	CcSEcCtD
Scopolamine—CHRM1—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.0034	0.0106	CbGpPWpGaD
Scopolamine—CHRM3—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00339	0.0105	CbGpPWpGaD
Scopolamine—Arrhythmia—Doxorubicin—bone cancer	0.00338	0.00498	CcSEcCtD
Scopolamine—Nausea—Cisplatin—bone cancer	0.00336	0.00495	CcSEcCtD
Scopolamine—CHRM2—Calcium Regulation in the Cardiac Cell—RGS1—bone cancer	0.00336	0.0104	CbGpPWpGaD
Scopolamine—Vision blurred—Epirubicin—bone cancer	0.00335	0.00494	CcSEcCtD
Scopolamine—Mental disorder—Doxorubicin—bone cancer	0.00331	0.00488	CcSEcCtD
Scopolamine—Erythema—Doxorubicin—bone cancer	0.00329	0.00485	CcSEcCtD
Scopolamine—Agitation—Epirubicin—bone cancer	0.00327	0.00482	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.00322	0.00474	CcSEcCtD
Scopolamine—CHRM3—Regulation of insulin secretion—GNA11—bone cancer	0.00321	0.00999	CbGpPWpGaD
Scopolamine—Vertigo—Epirubicin—bone cancer	0.0032	0.00471	CcSEcCtD
Scopolamine—Confusional state—Methotrexate—bone cancer	0.00313	0.00461	CcSEcCtD
Scopolamine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00312	0.00972	CbGpPWpGaD
Scopolamine—Vision blurred—Doxorubicin—bone cancer	0.0031	0.00457	CcSEcCtD
Scopolamine—CHRM3—GPCRs, Other—SMO—bone cancer	0.00307	0.00956	CbGpPWpGaD
Scopolamine—Nervous system disorder—Methotrexate—bone cancer	0.00304	0.00449	CcSEcCtD
Scopolamine—CHRM2—GPCRs, Other—SMO—bone cancer	0.00304	0.00946	CbGpPWpGaD
Scopolamine—Agitation—Doxorubicin—bone cancer	0.00303	0.00446	CcSEcCtD
Scopolamine—Skin disorder—Methotrexate—bone cancer	0.00301	0.00444	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.00301	0.00444	CcSEcCtD
Scopolamine—Hyperhidrosis—Methotrexate—bone cancer	0.003	0.00442	CcSEcCtD
Scopolamine—Dry mouth—Epirubicin—bone cancer	0.00296	0.00437	CcSEcCtD
Scopolamine—Vertigo—Doxorubicin—bone cancer	0.00296	0.00436	CcSEcCtD
Scopolamine—Confusional state—Epirubicin—bone cancer	0.00293	0.00432	CcSEcCtD
Scopolamine—Oedema—Epirubicin—bone cancer	0.0029	0.00428	CcSEcCtD
Scopolamine—Hypotension—Methotrexate—bone cancer	0.0029	0.00427	CcSEcCtD
Scopolamine—Nervous system disorder—Epirubicin—bone cancer	0.00285	0.0042	CcSEcCtD
Scopolamine—Tachycardia—Epirubicin—bone cancer	0.00283	0.00418	CcSEcCtD
Scopolamine—Skin disorder—Epirubicin—bone cancer	0.00282	0.00416	CcSEcCtD
Scopolamine—CHRM4—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.00282	0.00877	CbGpPWpGaD
Scopolamine—Hyperhidrosis—Epirubicin—bone cancer	0.00281	0.00414	CcSEcCtD
Scopolamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00278	0.0041	CcSEcCtD
Scopolamine—Somnolence—Methotrexate—bone cancer	0.00276	0.00407	CcSEcCtD
Scopolamine—Dry mouth—Doxorubicin—bone cancer	0.00274	0.00404	CcSEcCtD
Scopolamine—Hypotension—Epirubicin—bone cancer	0.00271	0.004	CcSEcCtD
Scopolamine—Confusional state—Doxorubicin—bone cancer	0.00271	0.00399	CcSEcCtD
Scopolamine—CHRM5—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.0027	0.00839	CbGpPWpGaD
Scopolamine—Oedema—Doxorubicin—bone cancer	0.00269	0.00396	CcSEcCtD
Scopolamine—Fatigue—Methotrexate—bone cancer	0.00268	0.00394	CcSEcCtD
Scopolamine—Pain—Methotrexate—bone cancer	0.00265	0.00391	CcSEcCtD
Scopolamine—Nervous system disorder—Doxorubicin—bone cancer	0.00264	0.00388	CcSEcCtD
Scopolamine—Tachycardia—Doxorubicin—bone cancer	0.00262	0.00387	CcSEcCtD
Scopolamine—Skin disorder—Doxorubicin—bone cancer	0.00261	0.00385	CcSEcCtD
Scopolamine—Hyperhidrosis—Doxorubicin—bone cancer	0.0026	0.00383	CcSEcCtD
Scopolamine—Somnolence—Epirubicin—bone cancer	0.00258	0.00381	CcSEcCtD
Scopolamine—Feeling abnormal—Methotrexate—bone cancer	0.00256	0.00377	CcSEcCtD
Scopolamine—CHRM3—Integration of energy metabolism—GNA11—bone cancer	0.00253	0.00786	CbGpPWpGaD
Scopolamine—Hypotension—Doxorubicin—bone cancer	0.00251	0.0037	CcSEcCtD
Scopolamine—Fatigue—Epirubicin—bone cancer	0.0025	0.00369	CcSEcCtD
Scopolamine—Pain—Epirubicin—bone cancer	0.00248	0.00366	CcSEcCtD
Scopolamine—Constipation—Epirubicin—bone cancer	0.00248	0.00366	CcSEcCtD
Scopolamine—CHRM1—G alpha (q) signalling events—GRM1—bone cancer	0.00246	0.00765	CbGpPWpGaD
Scopolamine—SI—Disease—ENO2—bone cancer	0.00245	0.00763	CbGpPWpGaD
Scopolamine—Abdominal pain—Methotrexate—bone cancer	0.00245	0.00362	CcSEcCtD
Scopolamine—Body temperature increased—Methotrexate—bone cancer	0.00245	0.00362	CcSEcCtD
Scopolamine—CHRM3—G alpha (q) signalling events—GRM1—bone cancer	0.00245	0.00762	CbGpPWpGaD
Scopolamine—Feeling abnormal—Epirubicin—bone cancer	0.00239	0.00353	CcSEcCtD
Scopolamine—Somnolence—Doxorubicin—bone cancer	0.00239	0.00352	CcSEcCtD
Scopolamine—CHRM2—G alpha (i) signalling events—GRM4—bone cancer	0.00233	0.00725	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—RGS1—bone cancer	0.00233	0.00725	CbGpPWpGaD
Scopolamine—Fatigue—Doxorubicin—bone cancer	0.00232	0.00342	CcSEcCtD
Scopolamine—Constipation—Doxorubicin—bone cancer	0.0023	0.00339	CcSEcCtD
Scopolamine—Pain—Doxorubicin—bone cancer	0.0023	0.00339	CcSEcCtD
Scopolamine—Abdominal pain—Epirubicin—bone cancer	0.0023	0.00338	CcSEcCtD
Scopolamine—Body temperature increased—Epirubicin—bone cancer	0.0023	0.00338	CcSEcCtD
Scopolamine—SI—Disease—DHFR—bone cancer	0.00228	0.00708	CbGpPWpGaD
Scopolamine—CHRM5—G alpha (q) signalling events—GNA11—bone cancer	0.00225	0.007	CbGpPWpGaD
Scopolamine—Asthenia—Methotrexate—bone cancer	0.00223	0.00328	CcSEcCtD
Scopolamine—Feeling abnormal—Doxorubicin—bone cancer	0.00221	0.00326	CcSEcCtD
Scopolamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.0022	0.00684	CbGpPWpGaD
Scopolamine—Pruritus—Methotrexate—bone cancer	0.0022	0.00324	CcSEcCtD
Scopolamine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GRM1—bone cancer	0.00219	0.00682	CbGpPWpGaD
Scopolamine—Body temperature increased—Doxorubicin—bone cancer	0.00212	0.00313	CcSEcCtD
Scopolamine—Abdominal pain—Doxorubicin—bone cancer	0.00212	0.00313	CcSEcCtD
Scopolamine—CHRM4—GPCR ligand binding—GRM4—bone cancer	0.00212	0.0066	CbGpPWpGaD
Scopolamine—Asthenia—Epirubicin—bone cancer	0.00208	0.00307	CcSEcCtD
Scopolamine—SI—Metabolism—ENO2—bone cancer	0.00206	0.00639	CbGpPWpGaD
Scopolamine—Pruritus—Epirubicin—bone cancer	0.00205	0.00303	CcSEcCtD
Scopolamine—Dizziness—Methotrexate—bone cancer	0.00205	0.00303	CcSEcCtD
Scopolamine—CHRM5—GPCR ligand binding—GRM4—bone cancer	0.00203	0.00632	CbGpPWpGaD
Scopolamine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00201	0.00626	CbGpPWpGaD
Scopolamine—Vomiting—Methotrexate—bone cancer	0.00197	0.00291	CcSEcCtD
Scopolamine—Rash—Methotrexate—bone cancer	0.00196	0.00288	CcSEcCtD
Scopolamine—Dermatitis—Methotrexate—bone cancer	0.00196	0.00288	CcSEcCtD
Scopolamine—Headache—Methotrexate—bone cancer	0.00194	0.00287	CcSEcCtD
Scopolamine—Asthenia—Doxorubicin—bone cancer	0.00193	0.00284	CcSEcCtD
Scopolamine—Dizziness—Epirubicin—bone cancer	0.00192	0.00283	CcSEcCtD
Scopolamine—SI—Metabolism—DHFR—bone cancer	0.00191	0.00593	CbGpPWpGaD
Scopolamine—Pruritus—Doxorubicin—bone cancer	0.0019	0.0028	CcSEcCtD
Scopolamine—CHRM1—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.0019	0.00591	CbGpPWpGaD
Scopolamine—CHRM3—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.00189	0.00589	CbGpPWpGaD
Scopolamine—CHRM2—Calcium Regulation in the Cardiac Cell—GNA11—bone cancer	0.00188	0.00583	CbGpPWpGaD
Scopolamine—Vomiting—Epirubicin—bone cancer	0.00185	0.00272	CcSEcCtD
Scopolamine—Nausea—Methotrexate—bone cancer	0.00184	0.00272	CcSEcCtD
Scopolamine—CHRM4—GPCR ligand binding—GRM1—bone cancer	0.00184	0.00572	CbGpPWpGaD
Scopolamine—Rash—Epirubicin—bone cancer	0.00183	0.0027	CcSEcCtD
Scopolamine—Dermatitis—Epirubicin—bone cancer	0.00183	0.0027	CcSEcCtD
Scopolamine—Headache—Epirubicin—bone cancer	0.00182	0.00268	CcSEcCtD
Scopolamine—SI—Metabolism—GNA11—bone cancer	0.00178	0.00554	CbGpPWpGaD
Scopolamine—Dizziness—Doxorubicin—bone cancer	0.00178	0.00262	CcSEcCtD
Scopolamine—CHRM5—GPCR ligand binding—GRM1—bone cancer	0.00176	0.00548	CbGpPWpGaD
Scopolamine—Nausea—Epirubicin—bone cancer	0.00173	0.00254	CcSEcCtD
Scopolamine—Vomiting—Doxorubicin—bone cancer	0.00171	0.00252	CcSEcCtD
Scopolamine—Rash—Doxorubicin—bone cancer	0.00169	0.0025	CcSEcCtD
Scopolamine—Dermatitis—Doxorubicin—bone cancer	0.00169	0.0025	CcSEcCtD
Scopolamine—Headache—Doxorubicin—bone cancer	0.00168	0.00248	CcSEcCtD
Scopolamine—SI—Disease—TGFBR2—bone cancer	0.00165	0.00513	CbGpPWpGaD
Scopolamine—SI—Metabolism—CYP3A4—bone cancer	0.00162	0.00502	CbGpPWpGaD
Scopolamine—Nausea—Doxorubicin—bone cancer	0.0016	0.00235	CcSEcCtD
Scopolamine—CHRM1—G alpha (q) signalling events—GNA11—bone cancer	0.00158	0.00493	CbGpPWpGaD
Scopolamine—CHRM3—G alpha (q) signalling events—GNA11—bone cancer	0.00158	0.00491	CbGpPWpGaD
Scopolamine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—bone cancer	0.00155	0.00482	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—GNA11—bone cancer	0.0015	0.00465	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—EZH2—bone cancer	0.00149	0.00463	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—GRM4—bone cancer	0.00143	0.00445	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—GRM4—bone cancer	0.00143	0.00443	CbGpPWpGaD
Scopolamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00142	0.00441	CbGpPWpGaD
Scopolamine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—GNA11—bone cancer	0.00141	0.00439	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—GRM4—bone cancer	0.00141	0.00439	CbGpPWpGaD
Scopolamine—CHRM4—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.0014	0.00436	CbGpPWpGaD
Scopolamine—SI—Metabolism—GSTP1—bone cancer	0.00138	0.0043	CbGpPWpGaD
Scopolamine—CHRM5—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.00134	0.00417	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—SMO—bone cancer	0.0013	0.00403	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00127	0.00394	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—SMO—bone cancer	0.00124	0.00386	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—GRM1—bone cancer	0.00124	0.00386	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—GRM1—bone cancer	0.00124	0.00384	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—GRM1—bone cancer	0.00122	0.00381	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—RGS1—bone cancer	0.0012	0.00373	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—GRM4—bone cancer	0.0012	0.00373	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—GRM4—bone cancer	0.00115	0.00357	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—RGS1—bone cancer	0.00115	0.00357	CbGpPWpGaD
Scopolamine—SI—Disease—KIT—bone cancer	0.00113	0.0035	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—RGS1—bone cancer	0.00109	0.00339	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—GRM4—bone cancer	0.00109	0.00339	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.00108	0.00335	CbGpPWpGaD
Scopolamine—SI—Disease—BRAF—bone cancer	0.00106	0.00329	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—GRM4—bone cancer	0.00104	0.00324	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—RGS1—bone cancer	0.00104	0.00324	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—GRM1—bone cancer	0.00104	0.00323	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—GRM1—bone cancer	0.000996	0.0031	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000981	0.00305	CbGpPWpGaD
Scopolamine—CHRM1—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000945	0.00294	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—GRM1—bone cancer	0.000944	0.00294	CbGpPWpGaD
Scopolamine—CHRM3—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000942	0.00293	CbGpPWpGaD
Scopolamine—CHRM2—Regulation of Actin Cytoskeleton—BRAF—bone cancer	0.000933	0.0029	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—NDUFA12—bone cancer	0.000918	0.00285	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—GRM1—bone cancer	0.000904	0.00281	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000894	0.00278	CbGpPWpGaD
Scopolamine—SI—Disease—MDM2—bone cancer	0.000887	0.00276	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000881	0.00274	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—SMO—bone cancer	0.000874	0.00272	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—SMO—bone cancer	0.000871	0.00271	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—SMO—bone cancer	0.000863	0.00268	CbGpPWpGaD
Scopolamine—SI—Disease—PTGS2—bone cancer	0.000855	0.00266	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—CDK4—bone cancer	0.000841	0.00261	CbGpPWpGaD
Scopolamine—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	0.000835	0.0026	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—GRM4—bone cancer	0.000808	0.00251	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—RGS1—bone cancer	0.000808	0.00251	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—GRM4—bone cancer	0.000806	0.00251	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—RGS1—bone cancer	0.000806	0.00251	CbGpPWpGaD
Scopolamine—CHRM4—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000803	0.0025	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—GRM4—bone cancer	0.000798	0.00248	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—RGS1—bone cancer	0.000798	0.00248	CbGpPWpGaD
Scopolamine—CHRM5—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000769	0.00239	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—NT5C3A—bone cancer	0.000761	0.00237	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000747	0.00232	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000745	0.00232	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—GRM4—bone cancer	0.000734	0.00228	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—RGS1—bone cancer	0.000734	0.00228	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—GRM4—bone cancer	0.000732	0.00228	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—RGS1—bone cancer	0.000732	0.00228	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—RGS1—bone cancer	0.000725	0.00225	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—GRM4—bone cancer	0.000725	0.00225	CbGpPWpGaD
Scopolamine—SI—Metabolism—PTGS2—bone cancer	0.000716	0.00223	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—GRM1—bone cancer	0.000701	0.00218	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—GRM1—bone cancer	0.000699	0.00217	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—GRM1—bone cancer	0.000692	0.00215	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—GNA11—bone cancer	0.00067	0.00208	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—SMO—bone cancer	0.000665	0.00207	CbGpPWpGaD
Scopolamine—CHRM2—SIDS Susceptibility Pathways—JUN—bone cancer	0.000655	0.00204	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—GRM4—bone cancer	0.000643	0.002	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—RGS1—bone cancer	0.000643	0.002	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000643	0.002	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—GNA11—bone cancer	0.000642	0.00199	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—SMO—bone cancer	0.000637	0.00198	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—GRM1—bone cancer	0.000637	0.00198	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—GRM1—bone cancer	0.000635	0.00197	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—GRM1—bone cancer	0.000628	0.00195	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—RGS1—bone cancer	0.000616	0.00192	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—GRM4—bone cancer	0.000616	0.00192	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—GNA11—bone cancer	0.000608	0.00189	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—IL3—bone cancer	0.000607	0.00189	CbGpPWpGaD
Scopolamine—SI—Disease—EGFR—bone cancer	0.000606	0.00188	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—GNA11—bone cancer	0.000583	0.00181	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—NDUFA12—bone cancer	0.000582	0.00181	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—IL3—bone cancer	0.000582	0.00181	CbGpPWpGaD
Scopolamine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000573	0.00178	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—GRM1—bone cancer	0.000558	0.00173	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000554	0.00172	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—IL3—bone cancer	0.000552	0.00172	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—JUN—bone cancer	0.000542	0.00168	CbGpPWpGaD
Scopolamine—CHRM1—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000541	0.00168	CbGpPWpGaD
Scopolamine—CHRM3—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.00054	0.00168	CbGpPWpGaD
Scopolamine—CHRM2—Regulation of Actin Cytoskeleton—EGFR—bone cancer	0.000534	0.00166	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—GRM1—bone cancer	0.000534	0.00166	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—IL3—bone cancer	0.000528	0.00164	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—NT5C3A—bone cancer	0.000483	0.0015	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—GNA11—bone cancer	0.000452	0.0014	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—GNA11—bone cancer	0.00045	0.0014	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—SMO—bone cancer	0.000448	0.00139	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—SMO—bone cancer	0.000447	0.00139	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—GNA11—bone cancer	0.000446	0.00139	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—SMO—bone cancer	0.000443	0.00138	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—GRM4—bone cancer	0.000434	0.00135	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—RGS1—bone cancer	0.000434	0.00135	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—GRM4—bone cancer	0.000432	0.00134	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—RGS1—bone cancer	0.000432	0.00134	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—RGS1—bone cancer	0.000428	0.00133	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—GRM4—bone cancer	0.000428	0.00133	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	0.000411	0.00128	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—GNA11—bone cancer	0.00041	0.00128	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—IL3—bone cancer	0.00041	0.00127	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—GNA11—bone cancer	0.000409	0.00127	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—IL3—bone cancer	0.000408	0.00127	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—GNA11—bone cancer	0.000405	0.00126	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—IL3—bone cancer	0.000404	0.00126	CbGpPWpGaD
Scopolamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000404	0.00126	CbGpPWpGaD
Scopolamine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	0.000402	0.00125	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	0.000396	0.00123	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—SMO—bone cancer	0.000393	0.00122	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—SMO—bone cancer	0.000376	0.00117	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—GRM1—bone cancer	0.000376	0.00117	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—GRM1—bone cancer	0.000375	0.00117	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—IL3—bone cancer	0.000372	0.00116	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—GRM1—bone cancer	0.000371	0.00115	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—IL3—bone cancer	0.000371	0.00115	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—IL3—bone cancer	0.000367	0.00114	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—GNA11—bone cancer	0.000359	0.00112	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—TP53—bone cancer	0.000358	0.00111	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	0.000357	0.00111	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—GNA11—bone cancer	0.000344	0.00107	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—ATF1—bone cancer	0.000334	0.00104	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—ENO2—bone cancer	0.000333	0.00104	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IL3—bone cancer	0.000326	0.00101	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—ATF1—bone cancer	0.00032	0.000995	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IL3—bone cancer	0.000312	0.00097	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—DHFR—bone cancer	0.000309	0.000961	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—GNA11—bone cancer	0.000289	0.000898	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	0.000281	0.000873	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TGFBR2—bone cancer	0.000279	0.000867	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TGFBR2—bone cancer	0.000267	0.00083	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—SMO—bone cancer	0.000265	0.000824	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—SMO—bone cancer	0.000264	0.000821	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—IGF1R—bone cancer	0.000262	0.000815	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—CYP3A4—bone cancer	0.000262	0.000814	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—SMO—bone cancer	0.000262	0.000813	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—IGF1R—bone cancer	0.000251	0.000781	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—GNA11—bone cancer	0.000242	0.000754	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—GNA11—bone cancer	0.000242	0.000751	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—GNA11—bone cancer	0.000239	0.000744	CbGpPWpGaD
Scopolamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	0.000236	0.000733	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—ATF1—bone cancer	0.000225	0.000701	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—ATF1—bone cancer	0.000225	0.000698	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—GSTP1—bone cancer	0.000224	0.000697	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—ATF1—bone cancer	0.000222	0.000692	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IL3—bone cancer	0.00022	0.000683	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IL3—bone cancer	0.000219	0.000681	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IL3—bone cancer	0.000217	0.000674	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—ENO2—bone cancer	0.000211	0.000657	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—DHFR—bone cancer	0.000196	0.00061	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—KIT—bone cancer	0.00019	0.000591	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TGFBR2—bone cancer	0.000188	0.000584	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TGFBR2—bone cancer	0.000187	0.000582	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TGFBR2—bone cancer	0.000185	0.000577	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GNA11—bone cancer	0.000183	0.00057	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—KIT—bone cancer	0.000182	0.000566	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—BRAF—bone cancer	0.000179	0.000556	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—IGF1R—bone cancer	0.000177	0.00055	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—IGF1R—bone cancer	0.000176	0.000548	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—IGF1R—bone cancer	0.000174	0.000543	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—EGFR—bone cancer	0.000173	0.000539	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—BRAF—bone cancer	0.000171	0.000532	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—CYP3A4—bone cancer	0.000166	0.000517	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—EGFR—bone cancer	0.000166	0.000516	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MDM2—bone cancer	0.00015	0.000466	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MDM2—bone cancer	0.000143	0.000446	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—GSTP1—bone cancer	0.000142	0.000442	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—JUN—bone cancer	0.00013	0.000405	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—KIT—bone cancer	0.000128	0.000399	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—KIT—bone cancer	0.000128	0.000397	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—MMP9—bone cancer	0.000127	0.000394	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—KIT—bone cancer	0.000127	0.000394	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—JUN—bone cancer	0.000125	0.000388	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—MMP9—bone cancer	0.000121	0.000377	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—BRAF—bone cancer	0.000121	0.000375	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—BRAF—bone cancer	0.00012	0.000374	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—BRAF—bone cancer	0.000119	0.00037	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—EGFR—bone cancer	0.000117	0.000363	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—EGFR—bone cancer	0.000116	0.000362	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—PTGS2—bone cancer	0.000116	0.000361	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—EGFR—bone cancer	0.000115	0.000359	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—EGFR—bone cancer	0.000102	0.000318	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MDM2—bone cancer	0.000101	0.000314	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MDM2—bone cancer	0.000101	0.000313	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MDM2—bone cancer	9.97e-05	0.00031	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—EGFR—bone cancer	9.8e-05	0.000305	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—JUN—bone cancer	8.78e-05	0.000273	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—JUN—bone cancer	8.75e-05	0.000272	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—JUN—bone cancer	8.66e-05	0.000269	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—TP53—bone cancer	8.59e-05	0.000267	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—MMP9—bone cancer	8.54e-05	0.000266	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—MMP9—bone cancer	8.51e-05	0.000265	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—MMP9—bone cancer	8.43e-05	0.000262	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—TP53—bone cancer	8.23e-05	0.000256	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—PTGS2—bone cancer	7.36e-05	0.000229	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—EGFR—bone cancer	6.9e-05	0.000215	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—EGFR—bone cancer	6.88e-05	0.000214	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—EGFR—bone cancer	6.81e-05	0.000212	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—TP53—bone cancer	5.79e-05	0.00018	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—TP53—bone cancer	5.77e-05	0.00018	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—TP53—bone cancer	5.72e-05	0.000178	CbGpPWpGaD
